Not too big. Not too small. Because of their intermediate size, macrocyclic peptides combine the potency and precise targeting of an antibody or biologic therapy with the stability and ease-of-administration of a pill. Swipe through to learn more. http://merck.us/3LuHxfn #DrawnToScience
About us
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
- Website
-
http://merck.us/2J2xAUh
External link for Merck
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Rahway, New Jersey
- Type
- Public Company
- Specialties
- Pharmaceutical
Locations
-
Primary
Get directions
126 E Lincoln Ave
P.O. Box 2000
Rahway, New Jersey 07065, US
-
Get directions
351 N Sumneytown Pike
North Wales, PA 19454, US
Employees at Merck
Updates
-
Today, we announced a strategic funding agreement with Blackstone, positioning our company to advance development of an investigational antibody-drug conjugate targeting TROP2 while we continue to advance our broad and expansive pipeline. Read more: http://merck.us/4nGnqZh
-
Join us today at 9 a.m. ET to learn more about our Q3 2025 #earnings: http://merck.us/4nv9Kjx
-
Our Q3 2025 #earnings results are live. Check out our full MRK financial summary and key highlights: http://merck.us/4nqAul9
-
Today, we announced the European Commission’s approval of a new treatment option for certain patients with head and neck squamous cell carcinoma. Read more here: http://merck.us/3L9ncfD
-
Today we announced positive topline Phase 3 trial results evaluating a combination regimen in #kidneycancer as we continue to work toward new treatment options for patients with renal cell carcinoma #RCC. http://merck.us/4hvVnu3
-
Today we announced positive topline results for our Phase 3 trial in advanced #kidneycancer in collaboration with Eisai US, reinforcing our commitment for patients with renal cell carcinoma #RCC. http://merck.us/4qvZYAr
-
We’re proud to announce the #FDA approval of a label update for a treatment option for patients with pulmonary arterial hypertension (#PAH). Learn more here: http://merck.us/4780Vr2
-
At #HLTH2025, we’re transforming intelligence to impact – hear from Dennis Flannelly, VP of Precision Medicine, Oncology, as he shares how AI-powered digital tools are being explored by our teams with the potential to bring research to patients faster joined by Aicha Diallo, MPH, CHES, Vice President of Programs, Patient Empowerment Network, and Eric Converse, CEO, PreciseDx
-
Nearly half of people with muscle-invasive #BladderCancer have had few options because they may be ineligible for cisplatin-based chemotherapy. The FDA has accepted our application for priority review of immunotherapy regimens that could become a new option for the nearly half of patients with MIBC who can’t receive cisplatin-based chemotherapy before surgery. Opportunities to address such unmet need are a reminder of why we do this work every day. Learn more: http://merck.us/474BE0T